Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin.

Bojkowski, C.; Arendt, Joséphine; Shih, Mu‐Chin; Markey, Sanford P.

doi:10.1093/clinchem/33.8.1343

Cited by 194 publications

(63 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these serotonin availability would be the most likely mechanism underlying the acute effect of fluvoxamine. In previous studies of healthy untreated subjects, urinary aMT6s concentrations have proved to be a reliable reflection, both qualitative and quantitative, of plasma melatonin levels [4,30]. However, in view of our findings of a lack of correlation between plasma melatonin and urinary aMT6s concentrations following fluvoxamine treatment, the possibility that fluvoxamine inhibits the hepatic metabolism of melatonin and therefore delays its clearance from the plasma must be considered.…”

Section: Discussionmentioning

confidence: 61%

Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Skene

Bojkowski

Arendt

1994

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

1. Acute administration of the specific serotonin uptake inhibitor, fluvoxamine (100 mg at 16.00 h), markedly increased nocturnal plasma melatonin concentrations, with high levels extending into the morning hours. 2. Acute administration of the noradrenaline uptake inhibitor, desipramine (DMI) (100 mg at 16.00 h), increased evening plasma melatonin concentrations. 3. Both drug treatments increased the duration of melatonin secretion, fluvoxamine significantly delaying the offset time and DMI significantly advancing the onset time. 4. The stimulatory effect of DMI on plasma melatonin was mirrored by increased urinary 6‐sulphatoxymelatonin (aMT6s) excretion. 5. On the contrary, there was no correlation between plasma melatonin and urinary aMT6s concentrations following fluvoxamine treatment, suggesting that fluvoxamine may inhibit the metabolism of melatonin. 6. Treatment with DMI increased plasma cortisol concentrations in the evening and early morning, treatment with fluvoxamine increased plasma cortisol at 03.00 h, 10.00 h and 11.00 h. 7. The drug treatments affected different aspects of the nocturnal plasma melatonin profile suggesting that the amplitude of the melatonin rhythm may depend upon serotonin availability and/or melatonin metabolism whilst the onset of melatonin production depends upon noradrenaline availability.

show abstract

Section: Discussionmentioning

confidence: 61%

Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Skene

Bojkowski

Arendt

1994

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have therefore examined the relationship between size at birth and overnight 6-sulphatoxymelatonin excretion in a population-based study of men and women, aged 20, whose birth measurements had been recorded in detail. The urinary melatonin metabolite, 6-sulphatoxymelatonin is a reliable indicator of melatonin production [Fellenberg et al, 1980;Bojkowski et al, 1987].…”

Section: Introductionmentioning

confidence: 99%

The impact of fetal size and length of gestation on 6‐sulphatoxymelatonin excretion in adult life

Kennaway¹,

Flanagan²,

Moore³

et al. 2001

Journal of Pineal Research

View full text Add to dashboard Cite

Recent studies have shown that intrauterine growth retardation or fetal distress in human infants is associated with a pronounced reduction in melatonin secretion during the first 3 months of life. It is not known whether these associations persist beyond infancy. We have therefore examined the relationship between birthsize and melatonin secretion in 159 men and women aged 20, born in Adelaide, South Australia. Melatonin secretion was estimated by analysing the overnight urinary excretion of 6-sulphatoxymelatonin. The overnight excretion ranged from 1.7 to 128.9 nmoles/subject, was higher in women than in men (46.5 vs 34.1 nmoles, P = 0.003) and was significantly negatively correlated with the body mass index (P = 0.006). Excretion correlated with both birthweight and ponderal index at birth (P = 0.04 and P = 0.01 respectively after adjustment for gestational age) and also fell with increased duration of gestation (P = 0.007). The effects of adult body mass index added to that of low birthweight in predicting 6-sulphatoxymelatonin excretion. These data suggest that urinary 6-sulphatoxymelatonin excretion was impaired in adults who were growth restricted prenatally or were delivered after 40 weeks gestation.

show abstract

“…Circulating melatonin is predominantly hydroxylated and conjugated with sulfate in the liver to form 6-sulfatoxymelatonin (aMT6s), which is excreted in high amounts in urine and has been used as an indicator of circulating melatonin [7][8][9][10]. Previous studies have found correlations between urinary melatonin excretion, especially nocturnal excretion, and circulating melatonin in plasma [5,[11][12][13][14][15][16] or in serum [17,18]. Urinary aMT6s has also been found to correlate with melatonin in plasma [11-13, 15, 16, 19, 20] or in serum [18,21,22].…”

Section: Introductionmentioning

confidence: 99%

“…Nevertheless, although several studies have concentrated on measuring melatonin secretion during the entire 24-hr period [13,14,[19][20][21][22][23][24], the main tendency has been to follow only nocturnal melatonin secretion. The excretion of aMT6s has been used as a measure of melatonin secretion in many earlier studies [11-16, 18-22, 24, 25], but that of urinary melatonin in only few [5,[15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions

Pääkkönen¹,

Mäkinen

Leppäluoto³

et al. 2005

Journal of Pineal Research

View full text Add to dashboard Cite

The aim of this study was to examine whether urinary melatonin, rather than urinary 6-sulfatoxymelatonin (aMT6s), can be used as an indicator of diurnally and seasonally changing melatonin secretion. The subjects (n=15) spent three separate 24-hr periods in a climatic chamber during winter (n=7) and summer (n=8). Blood and urine samples were obtained during each period at 2- to 5-hr intervals. Serum melatonin and urinary melatonin and aMT6s were assayed by radioimmunoassay. The serum melatonin levels increased nearly 10-fold from low daytime to high nocturnal values. The mean nocturnal increase of urinary melatonin was 1.7-fold and that of urinary aMT6s was 4.6-fold. Both urinary melatonin and aMT6s correlated significantly with area under the curve melatonin in serum during the night, during the day and throughout the entire 24-hr observation period in all cases. The ratio between urinary melatonin and aMT6s excretion showed significant diurnal variation, being ninefold higher at 16:00 hr than at 07:00 or at 09:00 hr. The ninefold decrease in the urinary melatonin/aMT6s excretion ratio between the evening and the morning may reflect increased liver metabolism of melatonin during the night. Both urinary melatonin and aMT6s are good indicators of melatonin secretion, but the variation is significantly smaller for the former molecule.

show abstract

Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin.

Cited by 194 publications

References 8 publications

Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

The impact of fetal size and length of gestation on 6‐sulphatoxymelatonin excretion in adult life

Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions

Contact Info

Product

Resources

About